HER2‐negative, node‐positive, high‐risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open‐label, phase 3 trial. Lancet Oncol. 2022;0(0):77‐90.
13. Prat A, Saura C, Pascual T, et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor‐ positive, HER2‐negative, luminal B breast cancer (CORALLEEN): an open‐label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):33‐43. 14...
“Historically, patients with HER2-positive metastatic colorectal cancer who have progressed following frontline therapy have had poor outcomes,” John Strickler, M.D., associate professor of medicine, Duke University Medical Center, and lead investigator for the MOUNTAINEER trial, said in a press rel...
home / around-the-practice / expert-insights-into-testing-and-treatment-for-her2-positive-metastatic-colorectal-cancer-mcrc A panel of experts discusses the evolution of biomarker testing in colorectal cancer and recent key data from the MOUNTAINEER and DESTINY-CRC01...
Tukysa with trastuzumab is indicated for second-line treatment of HER2-positive metastatic colorectal cancer, the first such therapy for this cancer. The FDA has granted an accelerated approval for Seagen’s Tukysa (tucatinib) for adult patients with unresectable or metastatic colorectal cancer. It ...
(Study ID: JSKN003-301). The study aims to compare the efficacy and safety of JSKN003 versus trastuzumab emtansine (T-DM1) for the treatment of HER2-positive advanced breast cancer. This marks the third Phase III clinical study initiated for JSKN003, following the trials in HER2 low-...
Verzenio (abemaciclib) is a treatment for both HR+, HER2-, high risk, node positive early breast cancer and for certain types of HR+, HER2- metastatic breast cancer.
Krop IE, Kim SB, Gonzalez-Martin A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC, Wildiers H, TH3RESA study collaborators (2014) Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, ...
Sara M. Tolaney, MD, MPH, discusses the efficacy of trastuzumab deruxtecan in the second-line setting and its potential to move into the first-line treatment of HER2-positive breast cancer. This is a modal window. The Playback API request failed for an unknown reason...
More than a decade ago, combination therapy with the anti-HER2 antibody trastuzumab and chemotherapy became the standard first-line treatment for patients with these types of tumours4. Although adding the anti-programmed death 1 (PD-1) antibody pembrolizumab to chemotherapy does not significantly ...